ESC 365 - Phase I gene therapy clinical trial design of RP-A601 in adult patients with PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM)

ESC Professional Premium Access

Phase I gene therapy clinical trial design of RP-A601 in adult patients with PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM)

Session: Cardiovascular trends: hospitalisations, trials, and genetic therapies

Topic: Trial Design

Speaker: Doctor M. Coggins (US)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Matthew Coggins

(United States of America)

0 follower

3 more presentations in this session

Reassessing pharmacological trials with positive composite outcome driven by reduction in nonfatal myocardial infarction: a systematic review and meta-analysis

Speaker: Mr H. Sun (CN)

Association between autonomic dysfunction, 12-year mortality and 10-year incident cardiovascular disease

Speaker: Doctor B. Hernandez (Dublin, IE)

First trimester maternal infections and offspring congenital heart defects: a systematic review and meta-analysis

Speaker: Miss H. Su (Leuven, BE)

Access the full session

Cardiovascular trends: hospitalisations, trials, and genetic therapies

Speakers: Doctor M. Coggins, Mr H. Sun, Doctor B. Hernandez, Miss H. Su

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources